About basal cell carcinoma
Basal cell carcinoma is the most common form of skin cancer and the most common of all cancers. In the United States alone, 4 million patients annually are diagnosed with basal cell carcinoma. Basal cell carcinoma manifests in many forms ranging from superficial to more invasive. Similar to actinic keratosis, the most common cause is exposure to sunlight and involves abnormal and uncontrolled cell growth. Although basal cell carcinoma rarely develops into melanoma, it is a great inconvenience to patients as it sometimes develops into large lesions in the form of open wounds, red spots or larger spheres in the skin. Basal cell carcinoma is mainly treated with surgery, but topical drugs are also used in cases where the lesion is superficial.
Planning of Phase IIa trial in basal cell carcinoma
The Company plans to take advantage of the opportunity to develop a topical treatment for superficial basal cell carcinoma through a continuation of the trials in actinic keratosis. Subsequently, a Phase IIa trial in basal cell carcinoma will be conducted in the second half of 2022. The Board of Directors estimates the capital requirements for the trial in question at approximately MSEK 20 in 2022, which the Board of Directors considers a limited amount compared with the potential value creation that it would imply for the shareholders of the company.
The global market is estimated at almost 6 billion USD in 2018, with a CAGR growth of nearly 9 percent until 2024. The Company is assessing the possibility of developing the same topical treatment for superficial basal cell carcinoma through a continuation of the actinic keratosis trials.